Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Dermatitis symbols : INCY save search
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
Published: 2023-10-13 (Crawled : 23:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.27%
H: 2.14%
C: 2.11%
opzelura children dermatitis
Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
Published: 2023-05-01 (Crawled : 22:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.3%
H: 1.49%
C: 0.95%
opzelura rapid dermatitis trial results
Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
Published: 2022-01-28 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.33%
H: 3.25%
C: 3.2%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.2%
H: 3.93%
C: 3.89%
olumiant fda atopic dermatitis program dermatitis baricitinib phase 3 lupus
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)
Published: 2021-09-21 (Crawled : 01:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.21%
H: 1.43%
C: 0.41%
treatment fda fda approval dermatitis approval atopic dermatitis
Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
Published: 2021-07-16 (Crawled : 14:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.3%
H: 0.44%
C: -2.37%
new drug baricitinib treatment dermatitis drug atopic dermatitis
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -3.27%
H: 0.39%
C: -2.47%
new drug treatment fda dermatitis drug atopic dermatitis application
Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021
Published: 2021-05-03 (Crawled : 14:15) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.02%
H: 0.74%
C: 0.14%
presentation dermatitis atopic dermatitis
Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis
Published: 2021-04-23 (Crawled : 18:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.5%
H: 1.3%
C: 1.16%
dermatitis phase 3 atopic dermatitis
OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses
Published: 2021-04-23 (Crawled : 17:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.01%
H: 1.12%
C: 0.9%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.5%
H: 1.3%
C: 1.16%
dermatitis phase 3 atopic dermatitis
Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
Published: 2021-04-06 (Crawled : 23:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.11%
H: 0.51%
C: -1.02%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.3%
H: 1.07%
C: 0.22%
new drug treatment dermatitis drug baricitinib atopic dermatitis
Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis
Published: 2021-02-19 (Crawled : 17:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.58%
H: 0.56%
C: -1.8%
dermatitis atopic dermatitis
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.